Jotbody develops single domain antibody-based products using a proprietary platform that prepares nanobodies through the vaccination of small shark species. This technology enables targeted treatment options for diseases such as cancer, enhancing therapeutic efficacy and patient outcomes.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional antibody development and production methods can be time-consuming, costly, and may not always yield antibodies with the desired specificity or affinity. Traditional methods for extracellular vesicle (EV) research also lack efficient tools for isolation, characterization, and functionalization, hindering advancements in diagnostics and therapeutics.
Solution
Jotbody leverages a proprietary platform using small shark species to develop single-domain antibody-based products, offering targeted treatment options for diseases like cancer. The company specializes in nanobody discovery services, nanobody-based research reagents, and innovative solutions for EV research. Jotbody provides comprehensive services, including antigen design and preparation, humanization and affinity maturation of nanobodies, protein expression, and conjugation modification. For EV research, Jotbody offers a range of services, including isolation and purification, characterization, omics, functionalization, and CDMO solutions, providing researchers with tools for EV analysis and manipulation.
Target Audience
Jotbody serves researchers and biopharmaceutical companies involved in drug discovery, diagnostics development, and basic research, particularly those focused on cancer, immunology, and extracellular vesicle-based therapies.
Features
- Nanobody discovery services using an exclusive shark platform
- Custom development of camelid VHH and shark vNAR
- Nanobody humanization and affinity maturation
- Protein expression and conjugation modification
- Extracellular vesicle isolation and purification services
- EV characterization services, including omics analysis
- EV functionalization services for targeted delivery
- CDMO solutions for extracellular vesicle-based products
- Nanobody reagents, including primary nanobodies and secondary antibodies
- Extracellular vesicle reagents, including buffers, serum, functionalization kits, isolation kits, and membrane labeling dyes